脂联素——一个关键adipokine代谢综合症。

文章的细节

引用

复制到剪贴板

IJ怀特黑德JP,理查兹AA, Hickman麦克唐纳GA,普林斯简森-巴顿

脂联素——一个关键adipokine代谢综合症。

糖尿病ob金属底座。2006;8 (3):264 - 80。

PubMed ID

16634986 (在PubMed

]

文摘

脂联素是最近描述adipokine被公认为胰岛素敏感性的主要监管机构和组织炎症。它是由脂肪组织(白色和棕色)和循环血液中高浓度。直接行动的肝脏,骨骼肌血管,改善肝胰岛素敏感性与突出的角色,增加燃料氧化(通过上调腺苷单磷酸盐激活蛋白激酶(AMPK)活动],减少血管炎症。脂联素存在于不同分子量的流通形式,由multimerization生产。最近的数据表明,高分子重量(高分子量)复合物在肝脏的主要行动。相比其他发病,脂联素的分泌和循环水平成反比的身体脂肪含量。在学科水平进一步降低糖尿病和冠心病。脂联素对抗许多影响肿瘤坏死因子-α(tnf),这反过来,抑制脂联素的生产。此外,从脂肪细胞脂联素分泌增强thiazolidinediones(也采取行动对抗tnf的影响)。因此,脂联素可能tnf的常见机制促进,thiazolidinediones压制,胰岛素抵抗和炎症。 Two adiponectin receptors, termed AdipoR1 and AdipoR2, have been identified and these are ubiquitously expressed. AdipoR1 is most highly expressed in skeletal muscle and has a prominent action to activate AMPK, and hence promote lipid oxidation. AdipoR2 is most highly expressed in liver, where it enhances insulin sensitivity and reduces steatosis via activation of AMPK and increased peroxisome-proliferator-activated receptor alpha ligand activity. T-cadherin, which is expressed in endothelium and smooth muscle, has been identified as an adiponectin-binding protein with preference for HMW adiponectin multimers. Given the low levels of adiponectin in subjects with the metabolic syndrome, and the beneficial effect of the adipokine in animal studies, there is exciting potential for adiponectin replacement therapy in insulin resistance and related disorders.

beplay体育安全吗DrugBank数据引用了这篇文章

药物靶点

药物	目标	类	生物	药理作用	行动
磷酸腺苷	5 ' -AMP-activated蛋白激酶亚基beta 1	蛋白质	人类	未知的	激活剂	细节